I am just going to hope that this essentially the "dump before the pump" as we head into Sanyal's ASH trial readout in Q1 2019 and the P2 NASH trial results submission to FDA for pivotal trial guidance. We also have the PNAFLD Phase 2 readout coming along in hopefully either Q1 or Q2 of 2019 as well as the C.Diff. readout sometime in 2019 as well.
I gotta say though, the fact that management couldn't attract enough interest in this company between the March 2018 Phase 2 NASH readout and now November 2018 where Immuron has fallen from .60 to now .26 says a lot.
